We are committed to Neuroscience

Our scientists are at the forefront in advancing the way we think about the brain and how we treat it. We believe the future of neuroscience lies in detecting and treating illness early to help prevent degeneration and disease progression.

Roche has a strong commitment to R&D. We have 75 new medicines in development, 14 of which are in neuroscience¹

• £8.4 billion invested globally in R&D in 2017, more than any other healthcare and biotech company² 
• 10,600 UK patients participated in Roche clinical trials in 2017 

MS, multiple sclerosis; R&D, research and development.

Reference:

1. https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm Accessed 08 October 2019 
2. Roche Impact in the UK 2018: Core Claims Document. F. Hoffmann-La Roche AG, 2018.

RXUKOCRE00087(3)

Date of preparation: October 2019